Back
Brainstorm Cell Therapeutics 10K Form
Sell
47
BCLI
Brainstorm Cell Therapeutics
Last Price:
$1.19
Seasonality Move:
75.37%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-14 | 10Q | BCLI/Brainstorm Cell Therapeutics Quarterly |
| 2023-11-14 | 10Q | BCLI/Brainstorm Cell Therapeutics Quarterly |
| 2023-08-14 | 10Q | BCLI/Brainstorm Cell Therapeutics Quarterly |
| 2023-05-15 | 10Q | BCLI/Brainstorm Cell Therapeutics Quarterly |
| 2022-11-14 | 10Q | BCLI/Brainstorm Cell Therapeutics Quarterly |
| 2022-08-15 | 10Q | BCLI/Brainstorm Cell Therapeutics Quarterly |
Receive BCLI News And Ratings
See the #1 stock for the next 7 days that we like better than BCLI
BCLI Financial Statistics
Sales & Book Value
| Annual Sales: | $0 |
|---|---|
| Cash Flow: | $-1.6M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $-0.94 |
| Price / Book: | 0 |
Profitability
| EPS (TTM): | -2.07000 |
|---|---|
| Net Income (TTM): | $-11.1M |
| Gross Margin: | $0 |
| Return on Equity: | 0% |
| Return on Assets: | 0% |
Brainstorm Cell Therapeutics Earnings Forecast
Key Brainstorm Cell Therapeutics Financial Ratios
-
Per Share Earnings over the last 23 years have been positive in 12 years.
Brainstorm Cell Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | BCLI |
| CUSIP: | 10501E |
| Website: | brainstorm-cell.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 0 |
| Quick Ratio: | 0 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
BCLI Technical Analysis vs Fundamental Analysis
Sell
47
Brainstorm Cell Therapeutics (BCLI)
is a Sell
Is Brainstorm Cell Therapeutics a Buy or a Sell?
-
Brainstorm Cell Therapeutics stock is rated a SellThe current Brainstorm Cell Therapeutics [BCLI] share price is $1.23. The Score for BCLI is 47, which is 6% below its historic median score of 50, and infers higher risk than normal.